Present therapies to minify hyperglycaemia and insulin resistance mainly target ATP-sensitive K+ channels (KATP) of pancreatic cells and PPAR-γ to enhance the insulin secretion and potential for GLUT expression, respectively. The gene discussed is SLC2A1; the disease is Hyperglycemia.